<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02433678</url>
  </required_header>
  <id_info>
    <org_study_id>1972</org_study_id>
    <nct_id>NCT02433678</nct_id>
  </id_info>
  <brief_title>An Investigation Into The Anti-hypertensive And Potential Anti-inflammatory Actions Of Dapagliflozin</brief_title>
  <official_title>An Investigation Into The Anti-hypertensive And Potential Anti-inflammatory Actions Of Dapagliflozin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University at Buffalo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kaleida Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University at Buffalo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center, prospective, randomized, placebo -controlled, parallel design and
      double blind study to evaluate oxidative stress, inflammation and hypertension markers and
      mediators before and after treatment with dapagliflozin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Two groups of 26 patients each (total 52 patients) with type 2 diabetes on oral agents will
      be included in the study. One group will be randomized to dapagliflozin (a dose of 5 mg daily
      will be titrated to 10 mg daily during the first week) while the other will be placebo. The
      patients will be treated for 12 weeks. Only half the patients (equal numbers in both groups)
      will be tested for the secondary endpoints related to postprandial and single dose induced
      changes. The primary endpoint of the study is to detect a significant difference in the
      percent change in fasting Nuclear factor-k B (NFκB) activation (DNA binding activity) in
      mononuclear cells (MNC) before and after dapagliflozin use (0 week vs. 12 weeks) as compared
      to placebo.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>difference in the percent change in fasting NFκB activation (DNA binding activity) in MNC before and after dapagliflozin use</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes in expression of inflammatory mediators</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Measure levels of p47phox, SOCS-3, IL-1b, JNK-1, TLR4 in mononuclear cells and TNF-a, IL-6, IL-1b, CRP in plasma</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in hypertension mediators will also be measured</measure>
    <time_frame>6 and 12 weeks</time_frame>
    <description>measure plasma levels of angiotensinogen, renin and angiotensin II , ANP, b-NP, cGMP and cAMP</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will be treated for 12 weeks with placebo once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 mg daily for the 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dapagliflozin</intervention_name>
    <description>SGLT-2 inhibitor for the treatment of type 2 diabetes</description>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <other_name>Firxiga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 20-80 years inclusive.

          -  Type 2 diabetes

          -  BMI ≥30 kg/m2

          -  Subjects on statins, ACE inhibitors, ARBs, thiazolidinediones and -antioxidants will
             be allowed as long as they are on stable doses of these -compounds and the dosage in
             not changed during the course of study. -Patients will be evenly distributed between
             the 2 groups based on statins, -ARBs, TZDs and ACE inhibitors use.

          -  HbA1c ≤ 8.0%

        Exclusion Criteria:

          -  Use of GLP-1 agonists or DPP-IV or SGLT-2 inhibitors therapy in the last 3 -months.

          -  Risk for pancreatitis, i.e., history of gallstones, alcohol abuse, and
             -hypertriglyceridemia.

          -  Coronary event or procedure (myocardial infarction, unstable angina, coronary -artery
             bypass, surgery or coronary angioplasty) in the previous 3 months.

          -  Hepatic disease: Severe hepatic insufficiency and/or significant abnormal liver
             -function defined as:

          -  aspartate aminotransferase (AST) &gt;3x upper limit of normal (ULN) and/or -alanine
             aminotransferase (ALT) &gt;3x ULN

          -  Total bilirubin &gt;2.0 mg/dL (34.2 µmol/L)

          -  Positive serologic evidence of current infectious liver disease including Hepatitis B
             viral antibody IGM, Hepatitis B surface antigen and Hepatitis C virus antibody

          -  (liver function tests more than 3 times the upper limit of normal)

          -  Renal impairment (serum eGFR &lt;60 ml/min)

          -  Any other life-threatening, non-cardiac disease

          -  Uncontrolled hypertension (BP &gt; 160/100 mm of Hg)

          -  Congestive Heart Failure class III or IV.

          -  Use of an investigational agent or therapeutic regimen within 30 days of study

          -  Participation in any other concurrent clinical trial

          -  pregnant or breastfeeding patients

          -  Volume depleted patients. Patients at risk for volume depletion due to co-existing
             conditions or concomitant medications, such as loop diuretics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paresh Dandona, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University at Buffalo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paresh Dandona, MD</last_name>
    <phone>7168981950</phone>
    <email>pdandona@kaleidahealth.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeanne Hejna, LPN</last_name>
    <phone>7168981950</phone>
    <email>Jeannehe@buffalo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ECMC Ambulatory Center, 3rd Floor</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paresh Dandona, MD</last_name>
      <phone>716-898-1940</phone>
      <email>pdandona@kaleidahealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Jeanne Hejna, LPN</last_name>
      <phone>716-898-1944</phone>
      <email>jeannehe@buffalo.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2015</study_first_submitted>
  <study_first_submitted_qc>April 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2015</study_first_posted>
  <last_update_submitted>November 15, 2016</last_update_submitted>
  <last_update_submitted_qc>November 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University at Buffalo</investigator_affiliation>
    <investigator_full_name>Paresh Dandona</investigator_full_name>
    <investigator_title>distinguished professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
    <mesh_term>Antihypertensive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

